Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...
The Alliance for Building Better Medicine (ABBM) and the Virginia Innovation Partnership Corporation (VIPC) celebrated Governor Glenn Youngkin's announcement of $120 million in private industry ...
A once-daily oral nonpeptide GLP-1 conferred significant improvements in body weight, HbA1c and other cardiometabolic ...
Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.
PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...
The results send a ‘clear, pragmatic message’ of IL-17 inhibition’s greater potency over IL-12/23 inhibition, an expert says.
DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual ...
Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...
Swiss pharma giant Novartis has been on a deal spree ahead of several major patent expiries. In late October it agreed a $12 ...
Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback